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Abstract
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition
and Allergies (NDA) was asked to deliver a scientiﬁc opinion on egg membrane hydrolysate as a novel
food (NF) pursuant to Regulation (EU) 2015/2283. The NF is a water-soluble hydrolysate of egg
membrane, produced by alkaline treatment of the thin layer lining the shells of chicken eggs. The main
constituents of the NF are elastin, collagen and glycosaminoglycans. The information provided on the
production process, batch-to-batch variability, composition and speciﬁcations of the NF is sufﬁcient and
does not raise safety concerns. The NF is proposed to be used as a food supplement for adults, at a
maximum daily amount of 450 mg. The consumption of the NF is not nutritionally disadvantageous.
One human study, which was not designed for safety but included a number of endpoints pertaining to
safety, did not raise safety concerns. The Panel considers that taking into account the information
provided and considering the nature, the source and the production process of the NF, there are no
safety concerns for the NF at the proposed conditions of use. The Panel concludes that the NF, egg
membrane hydrolysate, is safe as a food supplement at a dose of 450 mg/day. The target population
for the NF is the general adult population.
© 2018 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
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Summary
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition
and Allergies (NDA) was asked to deliver a scientiﬁc opinion on egg membrane hydrolysate as a novel
food (NF) pursuant to Regulation (EU) 2015/2283. The assessment of the safety of the NF follows the
methodology set out in the EFSA Guidance on the preparation and presentation of an application for
authorisation of a novel food in the context of Regulation (EU) 2015/2283 and in the Commission
Implementing Regulation (EU) 2017/2469.
The NF which is the subject of the application is a water-soluble hydrolysate of egg membrane,
produced by alkaline treatment of the thin layer lining the shells of chicken eggs. The NF is a protein-based,
water-soluble, off-white powder. Its main constituents are elastin, collagen and glycosaminoglycans. The
NF has been marketed outside the European Union (EU) under the trade name of BiovaFlexTM.
The information provided on the production process, batch-to-batch variability, composition and
speciﬁcations of the NF is sufﬁcient and does not raise safety concerns.
The NF is proposed to be used as a food supplement for adults, at a maximum daily amount of
450 mg.
Even though the alkaline treatment conditions employed during the manufacturing process will
result in partial racemisation of the amino acids in the NF and, thus, their limited digestibility/
bioavailability, taking into account the proposed conditions of use the Panel considers that the
consumption of the NF is not nutritionally disadvantageous.
There are no concerns for genotoxicity of the NF.
Of the two human studies provided with the NF, one study reported on safety related endpoints.
This study, even though not designed for safety but including a number of endpoints pertaining to
safety, did not raise safety concerns.
The Panel considers that taking into account the information provided and considering the nature,
the source and the production process of the NF, there are no safety concerns for the NF at the
proposed conditions of use.
The Panel concludes that the NF, egg membrane hydrolysate, is safe at the proposed conditions of
use, i.e. as a food supplement at a dose of 450 mg/day. The target population is the general adult
population.
Safety of egg membrane hydrolysate as a NF
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1. Introduction
1.1. Background and Terms of Reference as provided by the European
Commission
On 5 August 2016, the company Biova LLC submitted a request to the Danish Veterinary and Food
Administration (DVFA) in accordance with Article 4 of Regulation (EU) 258/19971 to place on the
market egg membrane hydrolysate as a novel food (NF).
On 7 June 2017, the DVFA forwarded to the Commission its initial assessment report, which came
to the conclusion that egg membrane hydrolysate meets the criteria for acceptance of a NF deﬁned in
Article (3)1 of Regulation (EU) 258/1997.
On 12 June 2017, the Commission forwarded the initial assessment report to the other Member
States (MS). Several MS raised objections or submitted comments.
The concerns of a scientiﬁc nature raised by the MS can be summarised as follows:
• Further information was requested on the manufacturing process.
• Further details on the composition of the NF were requested.
• One MS questioned the applicant’s rationale for not providing a full toxicological assessment
(‘based on the lack of toxicological effects of the source, i.e. egg membrane, which is
occasionally consumed with boiled eggs’).
• Concerns were raised by one MS concerning potential drug interactions between the NF and
medication taken by people with joint pain (who were the targeted study subjects in the
submitted human study and who might potentially be the target population for the NF).
Pursuant to Article 35(1) of Regulation (EU) 2015/22832, any request for placing a novel food on
the market within the Union submitted to a Member State in accordance with Article 4 of Regulation
(EC) No 258/97 of the European Parliament and of the Council concerning novel foods and novel foods
ingredients and for which the ﬁnal decision has not been taken before 1 January 2018, shall be treated
as an application submitted under Regulation (EU) 2015/2283.
On 20 April 2018, the European Commission asked EFSA to provide a scientiﬁc opinion by carrying
out the additional assessment for egg membrane as a novel food ingredient, in accordance with
Article 10(3) of Regulation (EU) 2015/2283.
2. Data and methodologies
2.1. Data
The safety assessment of this NF is based on data supplied in the application, the initial assessment
by the DVFA, the concerns and objections of a scientiﬁc nature raised by the other MS and the
responses from the applicant thereto.
The information in support of this application has been submitted through the Commission
e-submission portal (NF 2018/0124).
Administrative and scientiﬁc requirements for NF applications referred to in Article 10 of Regulation
(EU) 2015/2283 are listed in the Commission Implementing Regulation (EU) 2017/24693.
A common and structured format on the presentation of NF applications is described in the EFSA
guidance on the preparation and presentation of a NF application.4 As indicated in this guidance, it is
the duty of the applicant to provide all of the available (proprietary, conﬁdential and published)
1 Regulation (EU) No 258/97 of the European Parliament and of the Council of 27 January 1997 concerning novel foods and
novel food ingredients. OJ L 43, 14.2.1997, p. 1–6.
2 Regulation (EU) 2015/2283 of the European Parliament and of the Council on novel foods, amending Regulation (EU) No 1169/
2011 of the European Parliament and of the Council and repealing Regulation (EC) No 258/97 of the European Parliament and
of the Council and Commission Regulation (EC) No 1852/2001 (2013/0435 (COD). OJ L 327, 11.12.2015, p. 1–22.
3 Commission Implementing Regulation (EU) 2017/2469 of 20 December 2017 laying down administrative and scientiﬁc
requirements for applications referred to in Article 10 of Regulation (EU) 2015/2283 of the European Parliament and of the
Council on novel foods. OJ L 351, 30.12.2017, pp. 64–71.
4 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), Turck D, Bresson J-L, Burlingame B, Dean T,
Fairweather-Tait S, Heinonen M, Hirsch-Ernst KI, Mangelsdorf I, McArdle H, Naska A, Neuh€auser-Berthold M, Nowicka G,
Pentieva K, Sanz Y, Siani A, Sj€odin A, Stern M, Tome D, Vinceti M, Willatts P, Engel K-H, Marchelli R, P€oting A, Poulsen M,
Salminen S, Schlatter J, Arcella D, Gelbmann W, de Sesmaisons-Lecarre A, Verhagen H and van Loveren H, 2016. Guidance on
the preparation and presentation of an application for authorisation of a novel food in the context of Regulation (EU)
2015/2283. EFSA Journal 2016;14(11):4594, 24 pp. https://doi.org/10.2903/j.efsa.2016.4594
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scientiﬁc data, including both data in favour and not in favour to supporting the safety of the
proposed NF.
This NF application includes a request for the protection of proprietary data in accordance with
Article 26 of Regulation (EU) 2015/2283. The data requested by the applicant to be protected
comprise: detailed description of the manufacturing process, GRAS dossier (Biova, LLC, 2015),
proteomic analysis, bacterial reverse mutation test (ST&T Consultants, 2009b, unpublished), in vitro
micronucleus assay (Roy, 2016; unpublished), acute oral toxicity study (ST&T Consultants, 2009a,
unpublished), human study (ST&T Consultants, 2009c, unpublished), RAST-inhibition assay (Food
Allergy Research and Resource Program, 2008a, unpublished), quantitative egg allergen test (Food
Allergy Research and Resource Program, 2008b, unpublished) and a guinea pig sensitisation assay
(ST&T Consultants, 2009d, unpublished).
2.2. Methodologies
The assessment follows the methodology set out in the EFSA guidance on NF applications and the
principles described in the relevant existing guidance documents from the EFSA Scientiﬁc Committee.
The legal provisions for the assessment are laid down in Article 11 of Regulation (EU) 2015/2283 and
in Article 7 of the Commission Implementing Regulation (EU) 2017/2469.
This assessment concerns only risks that might be associated with the consumption of the NF
under the proposed conditions of use, and it is not an assessment of the efﬁcacy of the NF with
regard to any claimed beneﬁt.
3. Assessment
3.1. Introduction
The NF which is the subject of the application is a water-soluble hydrolysate of egg membrane,
produced by alkaline treatment of the thin layer lining the shells of chicken eggs. The powder is
proposed to be used as a food supplement. The NF has been marketed outside the EU under the
trade name of BiovaFlexTM.
3.2. Identity of the NF
The NF, i.e. egg membrane hydrolysate, is a protein-based, water-soluble, off-white powder. Its
main constituents are elastin, collagen and glycosaminoglycans.
The NF is derived from the eggs of farmed chicken hens (Gallus domesticus).
3.3. Production process
The NF is produced according to Good Manufacturing Practice (GMP) and Hazard Analysis Critical
Control Points (HACCP) principles.
The starting material for the production of the NF is eggshells from farmed chicken eggs produced
for human consumption. Information on the supplier of the eggshells has been provided. It is a United
States Department of Agriculture (USDA)-inspected egg-breaking facility located in the US.
The eggshells undergo hydromechanical separation in order to obtain the egg membranes, which
are then further processed using a patented solubilisation method. For the processing, pH and
temperature are increased and the egg membranes are kept under these conditions for a speciﬁed
amount of time. No solvents other than water are used. Details on the manufacturing process
including ﬂow charts have been provided. Following the solubilisation process, the solution is ﬁltered,
concentrated, spray-dried and packaged.
The Panel notes that the conditions employed during the manufacturing process (heat treatment
under alkaline pH) are expected to result in the formation of lysinoalanine as well as partial
racemisation of amino acids in the NF. However, taking into account the proposed daily intake of the
NF (i.e. 450 mg) and considering the dietary background intake from other processed protein-based
foods, the potential intake of lysinoalanine or D-amino acids via the NF is not considered to be of
safety concern.
The Panel considers that the production process is sufﬁciently described and does not raise safety
concerns.
Safety of egg membrane hydrolysate as a NF
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3.4. Compositional data
The NF consists primarily of proteins, peptides and amino acids (about 90%), with the remainder
being moisture (≤ 9%), ash (≤ 8%), fat (~ 1.8%), ﬁbre (2%) and traces of carbohydrates (< 0.01%).
The most abundant proteins in the NF are elastin (~ 25%) and collagen (~ 22%). Also the fraction
of glycosaminoglycans constitutes a sizable part (~ 18%) of the NF (values are the means of the
batches provided).
In order to conﬁrm that the manufacturing process is reproducible and adequate to produce on a
commercial scale a product with certain characteristics, the applicant provided analytical information
for three batches of the NF (see Table 1).
Information was provided on the accreditation (i.e. ISO/IEC 17025:2005 – general requirements for
the competence of testing and calibration laboratories) of the laboratory that conducted the analyses.
Additionally, the applicant provided the analytical results for a number of pesticides, dioxins and
antibiotics in the NF, which were all below the limit of detection.
Following a request from a MS for more details on the characterisation of the NF, the applicant
submitted information on the total amino acid composition of the NF and, in addition, compared it to
that of native egg membrane. Differences in the content of a number of amino acids were observed,
which might be owing to the hydrolysation step that occurs during the manufacturing process of the
NF. For example, the amide groups of glutamine and asparagine residues are partially hydrolysed
during the manufacturing process, increasing the content of glutamic acid and aspartic acid in the NF
Table 1: Batch-to-batch analysis of the NF
Parameter
Batch results of three commercial lots
P3095 P4132 P4252-1
Chemical
Total nitrogen-containing compounds (%) 90.79 89.69 89.47
Collagen (%) 20 22 25
Elastin (%) 26 26 22
Total glycosaminoglycans (%) 12.7 19.8 21
Calcium (%) 0.14 0.36 0.42
Physical
pH 6.6 6.9 6.8
Ash (%) 5.28 6.68 5.69
Moisture (%) 6.6 6.95 7.4
Water activity 0.207 0.246 0.244
Solubility (in water) Soluble Soluble Soluble
Bulk density (g/cc) 0.66 0.66 0.63
Heavy metal(s)
Arsenic (mg/kg) 0.02 0.02 0.02
Lead (mg/kg) 0.02 0.03 0.09
Cadmium (mg/kg) 0.01 0.01 0.01
Mercury (mg/kg) 0.01 0.01 0.01
Microbiology
Aerobic plate count (CFU/g) 150 60 90
Escherichia coli (MPN/g) < 3 < 3 < 3
Salmonella (in 25 g) negative negative negative
Coliforms (MPN/g) < 3 < 3 < 3
Staphylococcus aureus (CFU/g) < 10 < 10 < 10
Mesophilic spore count (CFU/g) 20 20 20
Thermophilic spore count (CFU/10 g) < 10 < 10 < 10
Yeast (CFU/g) < 10 < 10 < 10
Mould (CFU/g) < 10 < 10 10
CFU: colony forming units; MPN: most probable number.
Safety of egg membrane hydrolysate as a NF
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compared to native egg membrane. Furthermore, the drying step might dehydrate part of the
hydroxyproline in the native egg membrane to proline, leading to an increase of proline and a
decrease of hydroxyproline in the NF. The observed decrease of cystine in the NF might be owing to a
loss during processing prior to amino acid analysis.
The Panel considers that the information provided on the composition of the NF is sufﬁcient and
does not raise safety concerns.
3.4.1. Stability
In order to demonstrate the stability of the NF over the intended shelf life, speciﬁed as a period of
48 months in a cool and dry environment, the applicant provided the results of real-time stability
testing for one batch over 48 months at warehouse room temperature (relative humidity not
provided). The results for the parameters analysed (i.e. nitrogen-containing compounds, collagen,
elastin and total glycosaminoglycans; moisture, water activity, microbial growth) remained within the
limits set in the speciﬁcations.
Following a request from a MS for additional information concerning the stability of the NF, the
applicant provided the results of two additional batches, even though only up to 19.9 and
25.5 months, respectively. Over this time frame, the analysed parameters remained within the limits
set in the speciﬁcations.
The Panel considers that the data provided sufﬁcient information with respect to the stability of the
NF up to 20 months.
3.5. Speciﬁcations
The speciﬁcations of the NF are indicated in Table 2. They comprise the content of collagen,
elastin, and total glycosaminoglycans as well as other physicochemical parameters, limits for
contaminants such as heavy metals and microbiological speciﬁcations.
Table 2: Speciﬁcations of the NF
Parameter Limits Method
Chemical
Total nitrogen-containing compounds ≥ 88% Combustion according to AOAC 990.03 and AOAC
992.15
Collagen ≥ 15% SircolTM Soluble Collagen Assay (ELISA)
Elastin ≥ 20% FastinTM Elastin Assay (ELISA)
Total glycosaminoglycans ≥ 5% USP26 (chondroitin sulphate K0032 method)
Calcium ≤ 1% AOAC 965.17/985.01 mod.
Physical
pH 6.5–7.6 10% solution of NF at 25°C
Ash ≤ 8% AOAC 942.05
Moisture ≤ 9% AOAC 934.01
Water activity ≤ 0.3 Vapour pressure at 25°C
Solubility (in water) soluble 10% solution at 25°C
Bulk density ≥ 0.6 g/cc USP 616
Heavy metals
Arsenic ≤ 0.5 mg/kg ICP-MS according to AOAC 986.15
Microbiological
Aerobic plate count ≤ 2,500 CFU/g CMMEF, 4th Ed., 2001, Method 7.6
Escherichia coli ≤ 5 MPN/g FDA BAM 8th Ed., ch4
Salmonella Negative (in 25 g) AOAC 2003.09
Coliforms ≤ 10 MPN/g FDA BAM 8th Ed., ch4
Staphylococcus aureus ≤ 10 CFU/g FDA BAM 8th Ed., ch12
Mesophilic spore count ≤ 25 CFU/g AACC 4240
Thermophilic spore count ≤ 10 CFU/10 g AACC 4240
Safety of egg membrane hydrolysate as a NF
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The Panel considers that the information provided on the speciﬁcations of the NF is sufﬁcient and
does not raise safety concerns.
3.6. History of use of the NF and/or of its source
3.6.1. History of use of the source
The NF is produced from chicken eggs (Gallus domesticus), which have a long history of food use
within the EU.
Even though not consumed as a food as such, egg membranes may incidentally be consumed with
boiled eggs.
3.6.2. History of use of the NF
In 2009, the NF was notiﬁed as a New Dietary Ingredient (NDI) in the United States. Since then
approximately 17,000 kg of the NF have been sold (under the tradename of BiovaFlex®) in the US.
In 2015, the NF (i.e. BiovaFlex®) was notiﬁed by the applicant to be Generally Recognized as Safe
(GRAS) for use in food and food supplements (Biova LLC, 2015).
According to the information provided, no adverse reactions to egg membrane products on the US
market have been reported to date under the US FDA’s MedWatch adverse event reporting
programme.
3.7. Proposed uses and use levels
3.7.1. Target population
The target population proposed by the applicant is adults above 35 years of age.
3.7.2. Proposed uses and use levels
The applicant proposed to use the NF as an ingredient in food supplements, at a maximum dose of
450 mg per day.
3.8. Absorption, distribution, metabolism and excretion (ADME)
No ADME data have been provided on the NF.
3.9. Nutritional information
The applicant provided a nutritional analysis of the NF, which comprises information on the content
of nitrogen-containing compounds, ﬁbre, sodium, carbohydrates, fatty acids, vitamins and minerals in
the NF.
The NF is primarily (about 90%) composed of nitrogen-containing compounds (i.e. proteins,
peptides and amino acids). The proposed daily amount of 450 mg of the NF would result in an
additional intake of approximately 400 mg nitrogen-containing compounds per day.
The Panel notes that the alkaline treatment conditions employed during the manufacturing process
will result in partial racemisation of the amino acids in the NF and, consequentially, in limited
digestibility/bioavailability of such amino acids.
However, taking into account the proposed conditions of use (i.e. 450 mg/day), the Panel considers
that the consumption of the NF is not nutritionally disadvantageous.
Parameter Limits Method
Yeast ≤ 10 CFU/g AACC 9th Ed., 42-50
Mould ≤ 200 CFU/g AACC 9th Ed., 42-50
AACC: American Association for Clinical Chemistry; CFU: colony forming units; CMMEF: Compendium of Methods for the
Microbiological Examination of Foods; ELISA: enzyme-linked immunosorbent assay; FDA BAM: United States Food and Drug
Administration’s Bacteriological Analytical Manual; ICP-MS: inductively coupled mass spectrometry; MPN: most probable number;
USP: United States Pharmacopeia.
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3.10. Toxicological information
3.10.1. Genotoxicity
The applicant provided a bacterial reverse mutation assay (ST&T Consultants, 2009b, unpublished)
and an in vitro micronucleus assay (Roy, 2016, unpublished).
The bacterial reverse mutation assay (ST&T Consultants, 2009b, unpublished) was described as
following a non-GLP protocol. Reference was made to the publications by Ames et al. (1975) and
Maron and Ames (1983). For the assay ﬁve different strains of Salmonella Typhimurium were used, i.e.
TA97a, TA98, TA100, TA102 and TA1535. The NF, which was found to be completely soluble in sterile
water at 50 mg NF/mL (used as a stock solution), was tested at concentrations up to 5,000 lg/plate.
The testing included negative (i.e. solvent) and positive controls and was carried out with and without
metabolic activation (i.e. S9-mix from rat liver derived from AroclorTM-treated rats). All tests were
carried out in triplicate. The spontaneous reversion rates remained within accepted values for each
strain. All the ﬁve strains were sensitive to the mutagens used for the positive controls. No cytotoxicity
was observed. There was no increase in the number of revertant colonies following exposure to the NF
at concentrations up to 5,000 lg/plate in the presence or absence of metabolic activation.
The in vitro micronucleus assay (Roy, 2016, unpublished), which was conducted in compliance with
US FDA GLP Regulations, was carried out in a lymphocytic cell line (TK6) of human origin. The batch
of the NF used in the study was within the speciﬁcations set in section 3.5. As vehicle water was used.
In a preliminary test, the TK6 cells were exposed to vehicle alone and to nine different concentrations
of the NF with half-log dose spacing. Based on the ﬁndings of the pretest, the doses of the NF chosen
for the deﬁnitive assay were 100, 240, 350 and 500 lg/mL for each treatment condition. For the
assay, the cells were exposed to the NF for 4 h with and without S9-activation system, and for 27 h
without the S9-mix. No cytotoxicity (deﬁned as ≥ 50% decrease in population doubling relative to
vehicle control) was observed at any dose level. The dose levels selected for microscopic analysis were
240, 350 and 500 lg/mL for each treatment condition. A minimum of 1,000 mononucleate cells from
each culture were examined and scored for the presence of micronuclei. The frequency of micronuclei
in cells exposed to the NF was not signiﬁcantly increased at any dose level with or without metabolic
activation.
The Panel considers that taking into account the test results provided and considering the nature,
the source and the production process of the NF there are no concerns regarding genotoxicity of the
NF.
3.10.2. Toxicity studies
The applicant submitted one acute oral toxicity study (ST&T Consultants, 2009a, unpublished),
which was carried out in Sprague–Dawley albino rats. The rats (5/sex per group) were administered a
single oral dose of the NF at a dose of 5,000 mg/kg body weight (bw). The animals were observed at
1, 3, 6 and 24 h after treatment, and daily thereafter for a total of 14 days. All animals survived the
14-day observation period. The oral median lethal dose was thus concluded to be greater than
5,000 mg/kg bw.
No other toxicity studies were provided.
3.10.3. Human data
Two human studies with the NF were provided (ST&T Consultants, 2009c, unpublished; Jensen
et al., 2015) one of which reported on safety related endpoints (ST&T Consultants, 2009c,
unpublished).
This trial (ST&T Consultants, 2009c, unpublished) was an open-label uncontrolled pilot study
conducted in 42 subjects of at least 18 years with a history of arthritic-type joint pain or connective
tissue disorder with a reduced range of knee motion. The study subjects were instructed to consume
for 6 weeks 450 mg/day of the NF. The primary endpoint of the study was to assess a potential effect
of the NF on pain, stiffness, and discomfort of knee-associated musculoskeletal disorders. As
secondary endpoint the safety of the NF was investigated. Health evaluations of the study subjects
were performed at baseline and at weeks 2, 4 and 6. Adverse events and compliance were recorded
by study subjects in diaries and were reviewed at each visit. As part of the safety protocol, blood
chemistry, haematology and allergen antibody assays (i.e. concentration of immunoglobulin E (IgE)
antibodies to egg allergens) were performed. The haematology analysis included complete blood cell
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counts and concentrations of haematocrit and haemoglobin as well as cell morphology. The blood
chemistry analysis comprised non-fasting glucose, sodium, potassium, chloride, carbon dioxide, urea
nitrogen, creatinine, calcium, alkaline phosphatase, total protein, albumin and globulin. In addition,
aspartate aminotransferase (AST), alanine aminotransferase (ALT) and total bilirubin concentrations
were analysed to monitor liver function. Twelve subjects dropped out from the study. The reasons
were provided (i.e. personal (5), loss-to-follow up (2), high blood pressure (2), egg allergy (2) and
‘pressure’ (1)). The blood parameters analysed were all within normal ranges. No statistically
signiﬁcant changes from baseline were observed. No signiﬁcant increases in the concentration of IgE
antibodies to egg allergens were noticed in any subject. No adverse events were reported.
3.11. Allergenicity
In order to determine the allergenic potential of the NF, a radioallergosorbent test (RAST)-inhibition
assay was performed (Food Allergy Research and Resource Program, 2008a, unpublished), which is a
competitive radioimmunoassay that uses serum from egg-allergic individuals and which detects IgE-
binding (as described by Heﬂe et al., 1994). The RAST-inhibition curve of the NF was rather ﬂat when
compared to the curve of a whole egg sample (slope of 1.65 vs 23.42 for whole egg), indicating little
inhibition (i.e. binding) of egg speciﬁc-IgE by the NF.
The allergenicity of the NF was further investigated using the Neogen Veratox® Quantitative Egg
Allergen Test, which is speciﬁc for egg white. In three batches of the NF analysed, the amount of egg
white was below the limit of detection (i.e. 2.5 mg/kg). In a control sample of concentrated egg
membrane not having undergone solubilisation, the amount of egg white was 2,370 mg/kg (Food
Allergy Research and Resource Program, 2008b, unpublished).
The applicant also submitted a guinea pig sensitisation assay (Buehler), in which the topical
application of the NF to the skin of 12 Hartley albino guinea pigs for three weeks did not result in any
evidence of skin irritation or sensitisation (ST&T Consultants, 2009d, unpublished).
The applicant informed that notwithstanding the above results the NF will be labelled in accordance
with Regulation No 1169/20115, which requires labelling for substances or products with a potential to
cause allergies or intolerances (such as eggs and products thereof).
The Panel notes that the source of the NF is a recognised allergen and that, therefore, the NF is
potentially allergenic.
4. Discussion
The NF which is the subject of the application is a hydrolysate of egg membrane.
The information provided on the composition, the speciﬁcations, the production process and the
batch-to-batch variability of the NF is sufﬁcient and does not raise safety concerns.
The intention is to market the NF as a food supplement to adults, with a proposed maximum intake
of 450 mg/day.
The human study, which was not designed for safety but included a number of endpoints
pertaining to safety, did not raise safety concerns.
There are no concerns for genotoxicity of the NF.
The Panel considers that taking into account the information provided and considering the nature,
the source and the production process of the NF, there are no safety concerns for the NF at the
proposed conditions of use.
5. Conclusions
The Panel concludes that the NF, egg membrane hydrolysate, is safe at the proposed conditions of
use, i.e. as a food supplement at a dose of 450 mg/day. The target population is the general adult
population.
The Panel could not have reached its conclusion on the safety of the NF under the proposed
conditions of use without the detailed description of the manufacturing process for which data
protection was requested by the applicant.
5 Regulation (EU) No 1169/2011 of the European Parliament and of the Council of 25 October 2011 on the provision of food
information to consumers, amending Regulations (EC) No 1924/2006 and (EC) No 1925/2006 of the European Parliament and
of the Council, and repealing Commission Directive 87/250/EEC, Council Directive 90/496/EEC, Commission Directive 1999/10/
EC, Directive 2000/13/EC of the European Parliament and of the Council, Commission Directives 2002/67/EC and 2008/5/EC
and Commission Regulation (EC) No 608/2004. Ofﬁcial Journal of the European Union 2011, 54: 18–63.
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Steps taken by EFSA
1) Letter from the European Commission to EFSA with the request for a scientiﬁc opinion on the
safety of egg membrane as a NF. Ref. Ares(2018)2115205, dated 20 April 2018.
2) The information in support of this application has been submitted through the Commission
e-submission portal (NF 2018/0124).
3) On 13 March 2018 and on 23 March 2018, during validation of the application, EFSA asked
the applicant to provide missing information to complement the application.
4) On 20 April 2018, the validity of the application was conﬁrmed and the scientiﬁc evaluation
started.
5) During its meeting on 27 June 2018, the NDA Panel, having evaluated the data, adopted a
scientiﬁc opinion on the safety of egg membrane hydrolysate as a NF pursuant to Regulation
(EU) 2015/2283.
References
Ames BN, McCann J and Yamasaki E, 1975. Methods for detecting carcinogens and mutagens with the Salmonella/
mammalian-microsome mutagenicity test. Mutation Research, 31, 347–364.
Biova LLC, 2015. The Generally Recognized as Safe (GRAS) Status of BiovaFlex. Expert Panel Report. Prepared by:
AIBMR Life Sciences, Inc., Natural and Medicinal Products Research, Puyallup (WA) on behalf of Biova, LLC,
Johnston (IA); February 11, 2015.
Food Allergy Research and Resource Program, 2008a (unpublished). Analysis of solubilized egg shell membrane
using radioallergosorbent test-inhibition (RAST-inhibition). Food Allergy Research and Resource Program
(FARRP), University of Nebraska, Lincoln (NE); April 4, 2008.
Food Allergy Research and Resource Program, 2008b (unpublished). Results of egg testing of the eggshell derived
samples. Food Allergy Research and Resource Program (FARRP); Lincoln (NE); February 6, 2008.
Heﬂe SL, Lemanske RF Jr and Bush RK, 1994. Adverse reaction to lupine-fortiﬁed pasta. The Journal of Allergy and
Clinical Immunology, 94, 167–172.
Jensen GS, Lenninger MR, Beaman JL, Taylor R and Benson KF, 2015. Support of joint function, range of motion
and physical activity levels by consumption of a water-soluble egg membrane hydrolysate. Journal of Medicinal
Food, 18, 1042–1048.
Maron DM and Ames BN, 1983. Revised methods for the Salmonella mutagenicity test. Mutation Research, 113,
173–215.
Roy S, 2016 (unpublished). In vitro mammalian cell micronucleus assay in TK6 cells. (BioReliance Study No.
AE25MN.361ICH.BTL). Prepared by BioReliance Corporation, Rockville (MD) for NIS Labs, Klamath Falls (OR);
January 18, 2016.
ST&T Consultants, 2009a (unpublished). Acute oral toxicity in rats: ﬁnal report. (BiOva eggshell membrane powder
lot#: X8322 SKU#: 309; Exp. Ref. No. T08-6132). Prepared by ST&T Consultants, San Francisco (CA) for BiOva
LLC, Johnston (IA); January 15, 2009.
ST&T Consultants, 2009b (unpublished). Non-GLP Protocol: Bacterial reverse mutation assay: ﬁnal report. (BiOva
eggshell membrane powder lot#: X8322 SKU#: 309; Exp. Ref. No. M08-6105.0). Prepared by ST&T
Consultants, San Francisco (CA) for BiOva LLC, Johnston (IA); January 15, 2009.
ST&T Consultants, 2009c (unpublished). Human clinical safety and efﬁcacy pilot study BiovaFlexTM: An ingestible
egg shell membrane for the treatment of knee associated musculoskeletal pain and stiffness. ST&T
Consultants, San Francisco (CA); July 10, 2009.
ST&T Consultants, 2009d (unpublished). Guinea Pig Sensitization (Buehler): Final Report. (BiOva eggshell
membrane powder lot#: X8322 SKU#: 309; Exp. Ref. No. T08-6132). Prepared by ST&T Consultants, San
Francisco (CA) for BiOva LLC, Johnston (IA); February 05, 2009.
Abbreviations
AACC American Association for Clinical Chemistry
ADME absorption, distribution, metabolism and excretion
ALT alanine aminotransferase
AST aspartate aminotransferase
bw body weight
CFU colony forming units
CMMEF Compendium of Methods for the Microbiological Examination of Foods
DVFA Danish Veterinary and Food Administration
ELISA enzyme-linked immunosorbent assay
FDA BAM United States Food and Drug Administration’s Bacteriological Analytical Manual
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GLP Good Laboratory Practice
GMP Good Manufacturing Practice
GRAS Generally Recognized as Safe
HACCP Hazard Analysis Critical Control Points
ICP-MS inductively coupled mass spectrometry
IgE immunoglobulin E
MPN most probable number
MS Member State
NDA EFSA Panel on Dietetic Products, Nutrition and Allergies
NDI New Dietary Ingredient
NF novel food
RAST radioallergosorbent test
USDA United States Department of Agriculture
USP United States Pharmacopeia
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